MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Titan Pharmaceuticals Company Profile (OTCMKTS:TTNP)

Consensus Ratings for Titan Pharmaceuticals (OTCMKTS:TTNP) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00

Analysts' Ratings History for Titan Pharmaceuticals (OTCMKTS:TTNP)
Show:
DateFirmActionRatingPrice TargetActions
5/29/2016Roth CapitalReiterated RatingBuy$7.75 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Titan Pharmaceuticals (OTCMKTS:TTNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016Q116($0.12)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.10)($0.11)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015($0.02)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015($0.03)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.02)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.02)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/15/2013Q3 13($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Titan Pharmaceuticals (OTCMKTS:TTNP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Titan Pharmaceuticals (OTCMKTS:TTNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Titan Pharmaceuticals (OTCMKTS:TTNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/31/2016James R McnabDirectorBuy20,000$7.03$140,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Sunil BhonsleCEOBuy11,763$3.56$41,876.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Sunil BhonsleCEOBuy5,841$2.72$15,887.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016James R McnabDirectorBuy16,363$3.16$51,707.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Marc RubinChairmanBuy5,000$3.25$16,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Sunil BhonsleCEOBuy17,000$3.18$54,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Sunil BhonslePresidentBuy10,000$0.70$7,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Marc RubinChairmanBuy50,000$0.72$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Sunil BhonslePresidentBuy50,000$0.70$35,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Titan Pharmaceuticals (OTCMKTS:TTNP)
DateHeadline
06/29/16 09:38 AMStock Volatility in Review: Titan Pharmaceuticals Inc. (:TTNP) - Engelwood Daily
06/29/16 09:38 AMTitan Pharmaceuticals, Inc. (TTNP) Updated Price Targets - FTSE News
06/27/16 07:25 AMTitan Pharmaceuticals Added to Russell 3000 Index - MarketWatch
06/27/16 06:11 AMTitan Pharmaceuticals Added to Russell 3000 Index - [at noodls] - Press Releases SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/27/16 -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment ...
06/24/16 06:58 PMRecently Issued Stock Ratings For Titan Pharmaceuticals, Inc. (TTNP) - Fiscal Standard
06/20/16 06:29 PMTitan Pharmaceuticals Announces First Patients Treated With Probuphine® for Opioid Dependence
06/20/16 03:05 PMTITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi -
06/20/16 08:20 AMTitan Pharma (TTNP) Treats First Patients with Probuphine Implant - StreetInsider.com
06/20/16 08:20 AMThis Weeks Broker Views For Titan Pharmaceuticals, Inc. (TTNP) - Fiscal Standard
06/20/16 07:15 AMTitan Pharmaceuticals Announces First Patients Treated With Probuphine(R) for Opioid Dependence - [Marketwired] - Titan Pharmaceuticals, Inc. today announced that 10 patients received treatment last week with the Probuphine implant, making them the first patients in the United States to receive the medication since ...
06/16/16 10:13 AMTitan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine® for Opioid Dependence
06/16/16 08:30 AMProbuphine® (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting - [PR Newswire] - PRINCETON, N.J. and PALM SPRINGS, Calif., June 16, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals presented data yesterday from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine ...
06/15/16 07:46 AMTitan Pharma (TTNP) Will Present Four Post-Hoc Analyses from Probuphine Phase 3 in Opioid Dependence - StreetInsider.com
06/15/16 06:19 AMTitan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine(R) for Opioid Dependence - [at noodls] - Press Releases Poster on Analyses Presented at College of Problems of Drug Dependence 78th Annual Meeting PALM SPRINGS, CA -- (Marketwired) -- 06/15/16 -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today ...
06/13/16 09:53 AMTitan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine®
06/13/16 06:09 AMTitan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R) - [at noodls] - Press Releases More Than 800 Health Care Providers Already Certified Under the Probuphine REMS Program SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/13/16 -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ...
06/09/16 07:29 PMTitan Pharmaceuticals Inc. (NASDAQ:TTNP) Earnings Preview: Should Investors Be Nervous? - iStreetWire
06/07/16 07:12 PMSnapshot of Recent Traded Stocks: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Street Updates
06/04/16 06:59 PMAnalyst Recommended These Stocks for Investors: Titan Pharmaceuticals Inc. (NASDAQ:TTNP), Ascendis Pharma A/S ... - Beacon Chronicle
06/01/16 07:41 PMPrice Target Summary Report: Titan Pharmaceuticals Inc. (NASDAQ:TTNP), Hudson Pacific Properties, Inc. (NYSE:HPP) - Beacon Chronicle - Beacon ChroniclePrice Target Summary Report: Titan Pharmaceuticals Inc. (NASDAQ:TTNP), Hudson Pacific Properties, Inc. (NYSE:HPP)Beacon ChronicleTitan Pharmaceuticals Inc. (NASDAQ:TTNP) currently has High Price Target of $10. The Low and Mean Price Targets are $10 and $10 respectively. These price targets are a consensus analysis of 1 brokers. When having a look at Recommendation Trends of ...and more »
06/01/16 09:57 AMHealthcare Moving Stocks: Endo International plc (NASDAQ:ENDP) , Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) - Is stories - Is storiesHealthcare Moving Stocks: Endo International plc (NASDAQ:ENDP) , Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)Is storiesIn most recently trading session on 5/31/2016, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) climbed +2.48% while traded on 2.01 million shares versus it's an average volume of 455.74 thousand shares. The company recorded the last trade with the price of ...Endo International (NASDAQ:ENDP) moved up 1.05%: Titan (NASDAQ:TTNP), Flextronics International (NASDAQ ...Benchmark Monitorall 13 news articles »
05/31/16 07:22 PMTitan Pharmaceuticals, Inc. (TTNP) Director James R. Mcnab Purchases 20000 Shares - Let Me Know About This - Is storiesTitan Pharmaceuticals, Inc. (TTNP) Director James R. Mcnab Purchases 20000 SharesLet Me Know About ThisTitan Pharmaceuticals logo Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) Director James R. Mcnab acquired 20,000 shares of the business's stock in a transaction on Tuesday, May 31st. The stock was acquired at an average cost of $7.03 per share, for a ...Analysts Update on Stocks: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Exelixis, Inc. (NASDAQ:EXEL)Street UpdatesObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ...Is storiesTitan Pharmaceuticals, Inc. (NASDAQ:TTNP)'s director James Mcnab Made a Purchase of 20000 Shares of the CompanyHNNWsNews 4investorsall 5 news articles »
05/31/16 09:57 AMAnalyst Overview: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - Beacon Chronicle - Analyst Overview: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS)Beacon ChronicleLast Trade: The Company closed its last session at $6.86 Friday with the loss of -2.97%. The market capitalization of the company is $133.69 million, with the average Volume of $739,076.00. The stock currently has its 52-Week High range of $10.00 and ...and more »
05/31/16 09:57 AMWeekly Biotech Report Covering Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) FDA approval of probuphine - Market Exclusive - Market ExclusiveWeekly Biotech Report Covering Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) FDA approval of probuphineMarket ExclusiveThe situation with Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) developed similarly to what we predicted, so far. On May 27, the FDA approved Titan's Probuphine, an implant of buprenorphine for opiate addicts. In our previous report on Titan, we had said:.Analysts Update on Stocks: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Exelixis, Inc. (NASDAQ:EXEL)Street UpdatesObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ...Is storiesall 5 news articles »
05/30/16 10:26 PMShire PLC (ADR) (NASDAQ:SHPG) & Titan Pharmaceuticals, (NASDAQ:TTNP) Healthcare Traders Recap - Wall Street 24 - Shire PLC (ADR) (NASDAQ:SHPG) & Titan Pharmaceuticals, (NASDAQ:TTNP) Healthcare Traders RecapWall Street 24Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) declined -2.97% to $6.86. Braeburn Pharmaceuticals declares that the U.S. Food & Drug Administration (FDA) approved Probuphine, the first implant for the maintenance treatment of opioid dependence ...and more »
05/30/16 11:19 AMTitan Pharmaceuticals, Inc. (TTNP) Rating Reiterated by Roth Capital - Let Me Know About This - Titan Pharmaceuticals, Inc. (TTNP) Rating Reiterated by Roth CapitalLet Me Know About ThisTitan Pharmaceuticals logo Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP)'s stock had its “buy” rating reiterated by equities researchers at Roth Capital in a report released on Sunday. Shares of Titan Pharmaceuticals (OTCMKTS:TTNP) opened at 6.86 on ...
05/30/16 11:19 AMHC Stocks Zone: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) - HC Stocks Zone: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS)share market updates (press release)Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ended Friday session in red amid volatile trading. The shares closed down -0.21 points or -2.97% at $6.86 with 9.43 million shares getting traded. Post opening the session at $8.51, the shares hit an ...and more »
05/28/16 09:40 AMTitan Pharmaceuticals, Inc. (TTNP) Bull Gap Sends Options Volume Soaring - Schaeffers Research (blog) - Schaeffers Research (blog)Titan Pharmaceuticals, Inc. (TTNP) Bull Gap Sends Options Volume SoaringSchaeffers Research (blog)It's been a big week for biotechs, and today is no exception. Drugmaker Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), for example, has jumped 13% to $8.02, after the Food and Drug Administration (FDA) approved its Probuphine implant -- the first of its ...Titan Pharmaceuticals Inc. (TTNP) Is Up Sharply After FDA ApprovalRTT NewsWhy Titan Pharmaceuticals Shares Are Rising24/7 Wall St.Healthcare Stock That is Just so Hot: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)The Point ReviewRisers & Fallers -iStreetWire -Franklin Independentall 12 news articles »
05/27/16 11:58 AMFDA Approves New Opioid Addiction Treatment Tech - Bloomberg reported Thursday that the FDA granted approval to Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and partner Braeburn Pharmaceuticals for the first implant in the U.S. for the treatment of addiction to heroin and opioid-based painkillers. First To Market The product, Probuphine, will hit the market just as Congress and the White House have been working together to tackle what is being called an “epidemic” of heroin and ...Full story available on Benzinga.com
05/27/16 10:45 AMTitan Pharmaceuticals Announces FDA Approval of Probuphine® for the Treatment of Opioid Dependence - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the U.S. Food and Drug Administration has approved Probuphine® (buprenorphine) implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable ...
05/27/16 10:45 AMTitan Pharma Says FDA Approves Probuphine To Treat Opioid Dependence; Stock Up - (RTTNews.com) - Titan Pharmaceuticals, Inc. ( TTNP) announced that the U.S. Food and Drug Administration has approved Probuphine or buprenorphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable ...
05/27/16 10:45 AMThis tiny implant dampens pain drug dependence and just won FDA approval - ... sized device from Titan Pharmaceuticals Inc. won Food and Drug Administration approval Thursday as an aid in combatting dependence on pain-killing opioid drugs. The approval by South San Francisco-based Titan (NASDAQ: TTNP) is a huge corporate ...
05/27/16 10:45 AMTitan Pharma (TTNP) Announces Receipt of FDA Approval for Probuphine as Opioid Dependence Treatment - Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced that the U.S. Food and Drug Administration has approved Probuphine (buprenorphine) implant, the first product ...
05/27/16 10:45 AMTitan Pharmaceuticals, Inc. (NASDAQ:TTNP): That’s How Our Premium Members Made A Quick 40% Profit So Far - Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term ...
05/27/16 10:45 AMTitan Pharmaceuticals Inc. (TTNP) Is Up Sharply After FDA Approval - Titan Pharmaceuticals Inc. (TTNP) announced after the bell Thursday that the FDA approved Probuphine subdermal implant. The implant, which utilizes Titan's proprietary ProNeura technology, delivers buprenorphine continuously for up to six months.
05/27/16 09:15 AMWhy Titan Pharmaceuticals Shares Are Rising -
02/07/16 12:42 PMCould Titan Pharmaceuticals, Inc. Lose Strenght? The Stock Increases A Lot Today - Sonoran Weekly Review - Could Titan Pharmaceuticals, Inc. Lose Strenght? The Stock Increases A Lot TodaySonoran Weekly ReviewThe stock of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is a huge mover today! The stock increased 1.59% or $0.06 on February 5, hitting $3.84. About 324,342 shares traded hands. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has declined 12.28% since ...
02/02/16 12:44 PMCompelling Value In Titan After Positive AdCom Hearing - Seeking Alpha - Compelling Value In Titan After Positive AdCom HearingSeeking AlphaInvestors had to suffer through the disappointment of a previous rejection, and a restructuring of the relationship between Titan and its commercialization partner Braeburn. Now Titan finally appears to be on the cusp of FDA approval for Probuphine ...
02/01/16 12:32 PMLatest Analysts Reports On Titan Pharmaceuticals, Inc. (TTNP) - Risers & Fallers - Latest Analysts Reports On Titan Pharmaceuticals, Inc. (TTNP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Titan Pharmaceuticals, Inc. (TTNP). The latest broker reports which have been released state 0 analysts have a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, ...
01/26/16 11:50 AMTTNP: FDA Advisory Panel Recommends Approval of Probuphine By Solid Margin for Second Time… -
01/25/16 11:51 AMEye Catching Stocks: Apple Inc (NASDAQ:AAPL), Titan Pharmaceuticals (NASDAQ:TTNP), Callon Petroleum (NYSE ... - KC Register - Eye Catching Stocks: Apple Inc (NASDAQ:AAPL), Titan Pharmaceuticals (NASDAQ:TTNP), Callon Petroleum (NYSE ...KC RegisterApple Inc. (NASDAQ:AAPL) hired a top researcher in virtual and augmented reality, the latest sign that the tech giant is studying the rapidly advancing technologies. Apple confirmed a report in the Financial Times that it hired Doug Bowman, ...and more »
About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company developing therapeutics for the treatment of medical disorders. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. Titan's drug candidate, Probuphine, is in Phase III clinical study stage. The Company is also engaged in the development of its ProNeura-Ropinirole product to deliver dopamine agonists for the treatment of Parkinson's disease. The Company has licensed the rights to commercialize Probuphine in the United States and Canada to Braeburn Pharmaceuticals Sprl (Braeburn).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: TTNP
  • CUSIP:
Key Metrics:
  • Previous Close: $5.73
  • 50 Day Moving Average: $6.08
  • 200 Day Moving Average: $4.81
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $111.87M
  • Current Quarter EPS Consensus Estimate: $0.28 EPS
Additional Links:
Titan Pharmaceuticals (OTCMKTS:TTNP) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha